The overall response rates (ORRs) were 42.9% (3/7) for PD-1/PD-L1 monotherapy and 53.8% (7/13) for all patients (Fig. 5B), which is better than ORR for non-selective cancer patients (15%–35%) [37–42]. This evidence concerns the gene PDCD1 and cancer.